COVID 19 Drugs Flashcards
Nirmatrelvir MOA:
Prevents viral replication by inhibiting Mpro (main protease)
Nirmatrelvir ADR’s:
Dysgeusia, hypertension, myalgia, anaphylaxis, hypersensitivity reactions
Major Drug interactions for Nirmatrelvir:
Strong CYP3A inhibitor; interacts with drugs metabolized by this enzyme group
When taking Nirmatrelvir avoid concomitant use with drugs:
That may lead to serious or life-threatening reactions (e.g., alfuzosin, amiodarone, colchicine, simvastatin
Pharmacokinetics of Nirmatrelvir:
Peaks in plasma in 3 hours
60% protein bound
Minimally metabolized; excreted in urine and feces.
Ritonavir MOA:
Works concurrently with nirmatrelvir by inhibiting CYP3A and increasing its plasma concentration
Ritonavir Adverse Reactions:
hypertriglyceridemia, hepatotoxicity
Major Drug Interactions for Ritonavir:
Strong CYP3A inhibitor
Drugs that may lead to serious or life-threatening reactions (e.g., alfuzosin, amiodarone, colchicine, simvastatin
Pharmacokinetics for Ritonavir:
Peak plasma in 3.98 hours
98% to 99% bound to plasma proteins
Metabolized via CYP3A4 and CYP2D6; Excreted mainly in feces
What is Paxlovid?
Nirmatrelvir with Ritonavir together
Adverse Reactions for Paxlovid:
Dysgeusia, diarrhea, hypertension, myalgia, anaphylaxis.
Pharmacokinetics for Paxlovid:
Rapid absorption, high protein binding.
Major Drug Interactions for paxlovid:
Strong CYP3A inhibitor
Remdesevir MOA:
Inhibit COVID RNA dependent RNA polymerase & inhibits viral RNA synthesis.
ADR’s for Remdesevir:
elevated liver enzymes (ALT, AST), hypersensitivity reactions.
